ArticleScientific reports2026
Risk factor analysis and predictive model construction and evaluation of fractional uric acid excretion in Chinese inpatients with type 2 diabetes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Fractional excretion of uric acid (FEUA) is currently acknowledged as a new risk factor of nephropathy. Precise measurement of FEUA requires withdraw medication during the washout time and 24 h urine sample collecting, not always convenient, fostering construction of predictive models. No existing model could portrait FEUA. Our aim is to develop and evaluate a model which could predict FEUA based on several easily available factors. 2301 patients hospitalized in the Department of Endocrinology, Peking University People's Hospital were chose. 1510 cases enrolled during 2018-2024 were used to construct predictive models using linear regression and to perform internal validation. 791 cases enrolled in 2017 and 2025 were used as an external validation. Sex, SUA, SCr, and FPG closely related with FEUA in internal dataset. The predictive formula was: Ln (FEUA) = 1.9408 + 0.1462*gender (male=1female = 2) - 0.0031*SUA(µmol/L) + 0.0112*SCr(µmol/L) + 0.0068*FPG (mmol/L); Predicted FEUA = Exp(Ln(FEUA))*1.0265; 1.0265 was the Duan's smearing factor. Root mean squared errors (RMSE) between the observed and predicted FEUA was 1.690%. Spearman correlation coefficient was 0.7870 (P < 0.001). For predicting elevated FEUA (≥ 11%), the overall accuracy was 94.70%; ROC was 0.9552(95%CI: 0.9413 ~ 0.9691). Youden index (0.7814) at the cut-point (8.0257%) of FEUA was identified with a high sensitivity (0.9541) and specificity (0.8273). RMSE for 1-fold, 5-fold, 10-fold and leave-one-out cross-validation were 1.6898, 1.7087 ± 0.1716, 1.6964 ± 0.2761, and 1.7081, respectively. ROC values in subgroups of internal dataset were all higher than 0.949. In external dataset validation, Spearman correlation coefficient between observed and predicted FEUA was 0.7451(P < 0.001), ROC for elevated FEUA was 0.8946 (95% CI: 0.8545 ~ 0.9347). In validation on those excluded patients who were under medication, Spearman correlation coefficient between observed and predicted FEUA was 0.7899 (P < 0.001), ROC for elevated FEUA was 0.9029 (95% CI: 0.8817 ~ 0.9241). A stability of all indices was identified for subgroups of external dataset and those under medication. Our study identified an effective and practical FEUA predictive model in T2DM inpatients using linear regression with four common indexes: sex, SUA, SCr, FPG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.